Liege (Belgium) –
DMS Imaging (Euronext Brussels and Paris – BE0974289218 – DMSIM)
a French specialist in the development, design and manufacture of imaging systems, announces that in accordance with article 20 of the Prospectus Regulation, the prospectus (including the summary) relating to admission to the regulated markets of Euronext Brussels and Euronext Paris of the new DMS Imaging shares issued within the framework of the partial contribution of assets of the medical imaging division of DMS Group, has been approved by the FSMA (
Financial Services and Markets Authority
) as the competent authority under the Prospectus Regulation on December 20, 2022, then a notification was made to the AMF (Autorité des marchés financiers).
The prospectus constitutes an admission prospectus for the purposes of Article 3(3) of the Prospectus Regulation and has been prepared in accordance with the Prospectus Regulation and its Delegated Regulations, in relation to the admission to trading on the regulated markets of Euronext Brussels and Euronext Paris of 1,467,714,739 new DMS Imaging shares, namely:
151,925,266 new shares without nominal value issued by the company for the benefit of creditors in compensation for the contribution in kind of claims made by the company’s creditors; and
1,315,789,473 new shares without nominal value issued by the Company in favor of DMS Group in consideration for the contribution in kind of current account receivables and shares of the medical imaging division of DMS Group.
As a reminder, the legal, accounting and tax effective date of this contribution was set retroactively to 1
er
January 2022. DMS Imaging is 88.33% owned by DMS Group.
The admission prospectus is available on the DMS Imaging website, www.dms-imaging.com, Investors section, Other regulated information section.
The listing of DMS Imaging shares on the regulated markets of Euronext Brussels and Euronext Paris, suspended since September 5, 2022 at the request of the FSMA, pending the publication of the admission prospectus, will resume shortly.
DMS Imaging will report in the first days of January 2023 on its ambitions for the 2023 financial year.
Financial diary 2022
|
Date |
Event |
|
January 20, 2023 | Publication of 2022 annual revenue |
The publication will take place after the closing of the Euronext Paris market. This date is given as an indication, it is likely to be modified if necessary.
About DMS Imaging
Specialized in high technology in the service of medical diagnosis, DMS Imaging is now positioned as the French leader in the development, design and manufacture of imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology.
DMS Imaging is listed on the Euronext market in Brussels and Paris (ISIN: BE0974289218 – ticker: DMSIM).
More information at www.dms-imaging.com.
contacts
|
DMS Imaging | ||
Samuel SANCERNI | General manager | 04 67 50 49 00 |
|
FINANCE NEWS | ||
Mathieu OMNES | Investor Relations | 01 53 67 36 92 |
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
x51wYMVuZJrImnKbaspmmWmYl5xokpWbZ5SXlWpqZsiccJ1lnGaTnJ2dZnBonGht
– To check this key:
https://www.security-master-key.com.
Regulated information:
Press releases for the availability of documents:
– Methods of making available prospectuses
Full and original press release in PDF format:
https://www.actusnews.com/news/77737-dms-imaging_cp_approval-prospectus_20122022-fr-vdef.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com